News
Worldwide escalation in antimicrobial resistance (AMR) has sparked fear of a looming post-antimicrobial era. Antibiotic overuse and inappropriate use—including over-prescribing, inaccurate, and suboptimal prescribing—promotes bacterial evolution and resistance to treatment. Data suggests that there were an estimated 4.95 million deaths associated with bacterial AMR in 2019. The World Bank estimates that AMR could result in 1 trillion dollars in additional healthcare costs by 2050 if actions are not taken now to curb growing resistance.
Swipe to discover more
-
bioMérieux launches GENE-UP® TYPER, an innovative diagnostic solution for food industries to rapidly analyze the root cause of contamination of Listeria monocytogenes
bioMérieux, a world leader in the field of in vitro diagnostics, today announces the launch of GENE-UP® TYPER, a real-time PCR solution for rapid root cause analysis in the food industry. -
Bone and joint infections are complicated by antimicrobial resistance
Osteomyelitis – infection of the bone, and septic arthritis – joint infection, are serious medical conditions that can significantly impact a patient's quality of life. Bone and joint infections, often referred to as (BJIs), are notoriously difficult to treat and successful therapy requires organism-specific antimicrobial therapy at high doses for a prolonged duration.1 Diagnostics can support the identification and management of BJIs, while helping slow the progression of antimicrobial resistance (AMR). -
With E-Resale, bioMérieux innovates by giving a second life to its instruments
Launched last July, starting with Africa and Middle East, the E-Resale platform allows to purchase and sell second-hand bioMérieux instruments for clinical applications. This is an innovative offer in the field of circular economy and a first on the in vitro diagnostics market.
Enabling Decision-Making
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19